We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JWN
126
DELISTED
Nordstrom
JWN
$293K 0.05%
+12,000
New +$291K
KYMR icon
127
Kymera Therapeutics
KYMR
$8.94B
$274K 0.05%
10,000
– –
PHAT icon
128
Phathom Pharmaceuticals
PHAT
$692M
$268K 0.05%
42,800
-12,600
-23% -$76.5K
CLDX icon
129
Celldex Therapeutics
CLDX
$3.28B
$265K 0.05%
+14,600
New +$326K
UCFI
130
CN Healthy Food Tech Group
UCFI
$262K 0.05%
25,000
– –
VYGR icon
131
Voyager Therapeutics
VYGR
$201M
$255K 0.05%
75,545
-51,247
-40% -$239K
NRIX icon
132
Nurix Therapeutics
NRIX
$2.65B
$252K 0.05%
21,200
+10,200
+93% +$171K
GOSS icon
133
Gossamer Bio
GOSS
$87M
$250K 0.05%
227,228
-68,385
-23% -$79.1K
TXMD icon
134
TherapeuticsMD
TXMD
$24M
$250K 0.05%
270,160
– –
SYRE icon
135
Spyre Therapeutics
SYRE
$9.25B
$243K 0.05%
+15,033
New +$313K
DAWN
136
DELISTED
Day One Biopharmaceuticals
DAWN
$222K 0.04%
28,023
-25,000
-47% -$269K
ASND icon
137
Ascendis Pharma A/S
ASND
$16.8B
$219K 0.04%
1,402
-70,000
-98% -$10M
PYPD icon
138
PolyPid
PYPD
$92.8M
$217K 0.04%
80,080
– –
EXAS
139
DELISTED
Exact Sciences
EXAS
$216K 0.04%
5,000
– –
CNTX icon
140
Context Therapeutics
CNTX
$44.5M
$215K 0.04%
351,094
– –
MLTX icon
141
MoonLake Immunotherapeutics
MLTX
$1.55B
$212K 0.04%
5,424
-12,000
-69% -$517K
STOK icon
142
Stoke Therapeutics
STOK
$2.11B
$200K 0.04%
+30,085
New +$280K
CLBR
143
DELISTED
Colombier Acquisition Corp II
CLBR
$197K 0.04%
+18,513
New +$200K
QNCX icon
144
Quince Therapeutics
QNCX
$29.5M
$190K 0.04%
715
– –
DNLI icon
145
Denali Therapeutics
DNLI
$3.97B
$189K 0.04%
13,873
-30,953
-69% -$593K
WVE icon
146
Wave Life Sciences
WVE
$1.2B
$187K 0.03%
23,100
+1,400
+6% +$15.3K
PHGE icon
147
BiomX
PHGE
$1.85M
$166K 0.03%
+15,768
New +$220K
KURA icon
148
Kura Oncology
KURA
$850M
$165K 0.03%
+25,000
New +$195K
ABOS icon
149
Acumen Pharmaceuticals
ABOS
$176M
$161K 0.03%
146,183
+51,889
+55% +$74.1K
OGN icon
150
Organon & Co
OGN
$3.57B
$149K 0.03%
10,000
-30,200
-75% -$464K
4 5
6
7 8

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.